Recently, a genome-wide association study found links between AGAP1 variants and response to the anti-VEGF antibody Bevacizumab [64], which is used as a first-line treatment for HCC in combination with the anti-PD-L1 antibody Atezolizumab [2]. Here, VEGFA is linked to hepatocellular carcinoma.